Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly referred to as statins, are widely used in the treatment of dyslipidaemia, in addition to providing primary and secondary prevention against cardiovascular disease and stroke. Statins’ effects on the central nervous system (CNS), particularly on cognition and neurological disorders such as stroke and multiple sclerosis, have received increasing attention in recent years, both within the scientific community and in the media. Current understanding of statins’ effects is limited by a lack of mechanism-based studies, as well as the assumption that all statins have the same pharmacological effect in the central nervous system. This review aims to provide an updated discussion on the molecular mechanisms contributing to statins’ possible effects on cognitive function, neurodegenerative disease, and various neurological disorders such as stroke, epilepsy, depression and CNS cancers. Additionally, the pharmacokinetic differences between statins and how these may result in statin-specific neurological effects are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644 · cited 1×
“The pharmacophore of all statins bears resemblance to the endogenous HMG-CoA moiety (Table 1); it competitively binds to the catalytic domain of HMG-CoA reductase, causing steric hindrance and preventing HMG-CoA from accessing the active site [5,6].”
Inflammation is detrimental for neurogenesis in adult brain
Ekdahl, C. T., Claasen, J.-H., Bonde, S., Kokaia, Z., & Lindvall, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234031100 · Cited by 1,559
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030 · cited 1×
“The effect of statins on both cancer incidence and mortality remains unclear, with evidence for both reduced and increased cancer-related mortality associated with statin use [146,147].”
Cholesterol metabolism in the brain
Dietschy, J. M., & Turley, S. D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00003 · Cited by 906 · cited 2×
“The CNS does not rely largely on cholesterol from systemic circulation due to limited metabolic turnover during adulthood and the brain’s inherent capacity to synthesise its own cholesterol [25].”
High cholesterol level is essential for myelin membrane growth
Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R.-I., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005) · Nature Neuroscience · doi:10.1038/nn1426 · Cited by 799 · cited 1×
“Given that the vast majority of cholesterol acquisition in the CNS is through glial synthesis or neuronal reutilisation, with little to no reliance on systemic cholesterol pools, cholesterol availability in ODs is a rate-limiting step for successful myelination [101].”
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 1×
“The majority appear to support this initial finding, that statin treatment in patients without baseline cognitive impairment and before old age may have a beneficial role in protecting against the onset of AD [47,50,51,65].”
Cholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
Neurodegeneration and Inflammation in Parkinson's disease
Phani, S., Loike, J. D., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70064-5 · Cited by 263 · cited 1×
“It is the second most common chronic neurodegenerative disorder in adults over the age of 65 years [86].”
Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation
Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., & Landreth, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702640200 · Cited by 180 · cited 3×
“In experimental models of AD, the reduced production of Aβ has been attributed to reduction of neuroinflammation, and cells involved in the neuroinflammatory response [72,74].”
Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits
Tong, X.-K., Lecrux, C., & Hamel, E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0169-12.2012 · Cited by 160
Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020018 · Cited by 154 · cited 2×
“Swe neuroblastoma cells [70].”
Statins for people at low risk of cardiovascular disease – Authors' reply
Mihaylova, B., Emberson, J., Keech, A., Collins, R., & Baigent, C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)62027-3 · Cited by 146
Statin Therapy Inhibits Remyelination in the Central Nervous System
Miron, V. E., Zehntner, S. P., Kuhlmann, T., Ludwin, S. K., Owens, T., Kennedy, T. E., Bedell, B. J., & Antel, J. P. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080947 · Cited by 141
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136 · cited 1×
“Pharmacokinetic (PK) characteristics of commonly prescribed statins, data summarised from [5,11,13–23].”
Tong, X.-K., Nicolakakis, N., Fernandes, P., Ongali, B., Brouillette, J., Quirion, R., & Hamel, E. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.003 · Cited by 122
Clinical pharmacokinetics of statins
Garcia, M. J., Reinoso, R. F., Sanchez Navarro, A., & Prous, J. R. (2003) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2003.25.6.769652 · Cited by 121
Statins use and risk of depression: A systematic review and meta-analysis
Parsaik, A. K., Singh, B., M. Hassan, M., Singh, K., Mascarenhas, S. S., Williams, M. D., Lapid, M. I., Richardson, J. W., West, C. P., & Rummans, T. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.026 · Cited by 100 · cited 2×
“…a possible role for statins in the reduction of depression and depression-like symptoms [133–138], with a recent meta-analysis by Parsaik and colleagues concluding that statin use was associated with a lower risk for depression (adjusted odds ratio, 0.68; 95% confidence interval, 0.52–0.89) [1].”
InfluentialKurata, T., Miyazaki, K., Kozuki, M., Panin, V.-L., Morimoto, N., Ohta, Y., Nagai, M., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.067 · Cited by 98
Ludka, F. K., Zomkowski, A. D. E., Cunha, M. P., Dal-Cim, T., Zeni, A. L. B., Rodrigues, A. L. S., & Tasca, C. I. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.005 · Cited by 92
Statins and their influence on brain cholesterol
Cibičková, L. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.06.007 · Cited by 58
Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress
Lin, P.-Y., Chang, A. Y. W., & Lin, T.-K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.06.006 · Cited by 43 · cited 1×
“In rats exposed to chronic mild stress, simvastatin (5–10 mg/kg/day, 14 days) reversed some stress-induced behavioural changes comparable to imipramine, a tricyclic antidepressant [143].”
Cited by
Statin-Associated Side Effects
Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 739
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Post stroke depression: the sequelae of cerebral stroke
Das, J., & G.K., R. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.04.005 · Cited by 301
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Metadata
- Authors
- McFarland, A., Anoopkumar-Dukie, S., Arora, D., Grant, G., McDermott, C., Perkins, A., & Davey, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2014-11-10
- Volume
- 15
- Issue
- 11
- Pages
- 20607-20637
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2166094628
- Cited by
- 196
- References
- 27
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.